-
2022-502145-10-00
5
2023-06-06
Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor
-
2024-514080-25-00
5
2023-04-21
Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary P
-
2023-503501-11-00
5
2023-02-09
Metastatic Non-small Cell Lung Cancer
-
2024-512915-33-00
5
2022-12-22
Metastatic Colorectal Cancer
-
2023-505057-40-00
4
2022-12-02
Lung Cancer, Non-Small Cell
-
2023-505772-30-00
5
2022-11-09
Melanoma
-
2023-504195-14-00
5
2022-08-31
PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
-
2023-503999-24-00
5
2022-06-01
Patients With Locally Advanced (Stage III), Unresectable Non-small Cel
-
2023-507795-51-00
5
2022-05-17
atherosclerotic heart and blood vessel disease (the narrowing of arter
-
2023-503517-30-00
5
2022-04-01
Extensive-stage small-cell lung cancer
-
2023-506361-56-00
5
2022-04-01
Endometrial cancer
-
2024-512148-50-00
5
2022-03-03
Non-small cell lung cancer
-
2023-505615-21-00
5
2021-04-28
Muscle Invasive Bladder Cancer
-
2023-503500-87-00
11
2020-03-17
Muscle Invasive Bladder Cancer
-
2022-501973-37-00
5
2020-01-30
Endometrial cancer
-
2024-510826-16-00
5
2025-04-07
Rheumatoid Arthritis
-
2024-512549-18-00
4
2024-12-19
Weight management
-
2023-506664-14-00
5
2024-10-24
Rheumatoid Arthritis
-
2023-509412-28-00
4
2024-07-26
Type 2 Diabetes
-
2023-505842-24-00
5
2024-05-07
Moderate to Severe Plaque Psoriasis
-
2023-506092-10-00
4
2024-03-11
Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous
-
2022-502453-33-00
4
2024-02-26
Advanced Endometrial Cancer
-
2023-507358-34-00
4
2024-02-13
For the treatment of patients with chronic non-specific low back pain
-
2022-501310-57-00
4
2024-02-05
Endometriosis related pain